Rizzo JD, Lichtin AE, Woolf SH, et al. 2002. Use of erythropoietin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol, 20:4083-107. Schwartzberg LS, Yee LK, Senecal FM, et al. 2004. A randomized comparison of every-2-week darbepoetin alpha and weekly epoetin alpha for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist, 9:696-707. Senecal FM, Yee L, Gabrail N, et al. 2005. Treatment of chemotherapy- induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alpha 200 microg every 2 weeks versus epoetin alpha 40,000 U weekly. Clin Breast Cancer, 6:446-54. Shasha D, George MJ, Louis B, et al. 2003. Once-weekly dosing of epoetin- alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer, 98:1072-9. Smith RE Jr, Jaiyesimi IA, Meza LA, et al. 2001. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer, 84(Suppl.1):24-30. Smith RE Jr, Tchekmedyian NS, Chan D, et al. 2003. A dose- and schedule- finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer, 88:1851-8. Darbepoetin in anemia of cancer Stead RB, Lambert J, Wessels D, et al. 2006. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled,dose-escalation study in healthy volunteers. Blood, 108:1830-4. Terpos E, Mougiou A, Kouraklis A; The Greek MDS Study Group. 2003. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol, 118:174-80. Vadhan-Raj S, Mirtsching B, Charu V, et al. 2003. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy- induced anemia given darbepoetin alpha every two weeks. J Support Oncol, 1:131-8. Vansteenkiste J, Pirker R, Massuti B, et al. 2002. Double-blind, placebo- controlled, randomized phase iii trial of darbepoetin alpha in lung cancer patients receiving chemotherapy. J Natl Cancer Inst, 94:1211-20. Waltzman R, Croot C, Justice GR, et al. 2005. Randomized comparison of epoetin alpha (40,000 U weekly) and darbepoetin alpha (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist, 10:642-50. Witzig TE, Silberstein PT, Loprinzi CL, et al. 2005. Phase III, randomized, double-blind study of epoetin alpha compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol, 23:2606-17. Therapeutics and Clinical Risk Management 2007:3(2) 275